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ABSTRACT
Background. Polypharmacy (PP) and potentially inappropriate
medications (PIM) are highly prevalent in older adults with
cancer. This study systematically reviews the associations of
PP and/or PIM with outcomes and, through a meta-analysis,
obtains estimates of postoperative outcomes associated with
PP in this population.
Materials and Methods. We searched PubMed, Embase,
Web of Science, and Cochrane Register of Clinical Trials
using standardized terms for concepts of PP, PIM, and can-
cer. Eligible studies included cohort studies, cross-sectional
studies, meta-analyses, and clinical trials which examined
outcomes associated with PP and/or PIM and included older
adults with cancer. A random effects model included studies
in which definitions of PP were consistent to examine the
association of PP with postoperative complications.
Results. Forty-seven articles met the inclusion criteria.
PP was defined as five or more medications in 57% of the
studies. Commonly examined outcomes included chemo-
therapy toxicities, postoperative complications, functional
decline, hospitalization, and overall survival. PP was associ-
ated with chemotherapy toxicities (4/9 studies), falls (3/3
studies), functional decline (3/3 studies), and overall sur-
vival (2/11 studies). A meta-analysis of four studies indi-
cated an association between PP (≥5 medications) and
postoperative complications (overall odds ratio, 1.3; 95%
confidence interval [1.3–2.8]). PIM was associated with
adverse outcomes in 3 of 11 studies.
Conclusion. PP is associated with postoperative complica-
tions, chemotherapy toxicities, and physical and functional
decline. Only three studies showed an association between
PIM and outcomes. However, because of inconsistent defini-
tions, heterogeneous populations, and variable study designs,
these associations should be further investigated in prospec-
tive studies. The Oncologist 2020;25:e94–e108
Implications for Practice: Polypharmacy and potentially inappropriate medications (PIM) are prevalent in older adults with
cancer. This systematic review summarizes the associations of polypharmacy and PIM with health outcomes in older patients
with cancer. Polypharmacy and PIM have been associated with postoperative complications, frailty, falls, medication non-
adherence, chemotherapy toxicity, and mortality. These findings emphasize the prognostic importance of careful medication
review and identification of PIM by oncology teams. They also underscore the need to develop and test interventions to
address polypharmacy and PIM in older patients with cancer, with the goal of improving outcomes in these patients.
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INTRODUCTION
In the U.S., more than half of new cancer cases and about 70%
of cancer deaths occur in adults aged 65 years or older [1]. Com-
pared with younger cohorts, older adults are more likely to have
comorbid conditions for which medications are prescribed [2].
Older adults with cancer also have a higher rate of frailty and
geriatric syndromes compared with those without cancer [3]. For
patients receiving cancer treatment, chemotherapy and support-
ive care regimens often involve the prescription of multiple med-
ications. Because of these factors, older adults with cancer are at
high risk of polypharmacy (PP), defined as the simultaneous use
of multiple medications. In community-dwelling populations
of older adults without cancer, PP has been associated with
increased falls [4], hospitalization [5], and mortality [6].
There is a wide variability in the definition of PP in the existing
literature [7]. In one study of community-dwelling older adults with
cancer, 84% were on five or more medications and 43% were on
10 or more medications [8]. The use of five or more medications is
the most commonly used definition of PP in the literature, whereas
the use of 10 or more medications is commonly referred to as
“extreme PP” or “hyperpolypharmacy.”Multiple cutoffs are used in
the literature, and studies vary as to how medications are counted
(i.e., whether only scheduled prescription medications are
included, or whether supplements, over-the-counter medica-
tions, and as-needed medications are counted as well [8]).
Definitions of PP typically do not account for the appropri-
ateness of medications. PP increases the risk that one or more
medications is “potentially inappropriate”; these potentially
inappropriate medications (PIMs) have risks higher than antici-
pated benefits in older adults. PIMs may be assessed using
multiple validated instruments including the Beers criteria
[9], Screening Tool of Older Person’s Prescriptions (STOPP)
and Screening Tool to Alert to Right Treatment (START)
criteria [10], Zhan criteria [11], and medication appropri-
ateness index (MAI) [12]. In older adults, PIMs are associated
with increased risks of adverse drug events, hospitalizations,
and mortality [13], as well as higher health care costs [14].
However, supportive care regimens may include medications
(such as benzodiazepines for treatment of nausea) that would
otherwise be deemed PIM but may be clinically appropriate
based on oncology supportive care guidelines.
Although the literature on PP and PIM in older adults is
increasing, data in older adults with cancer remain sparse.
Extrapolation of data from the general population of older
adults is problematic: older adults with cancer have more
frailty and multimorbidity than patients without cancer, they
take more medications on average, and the initiation of che-
motherapy and supportive care regimens can significantly
increase the risk of drug-drug interactions and adverse drug
events [15]. It also remains unclear whether PP and PIM affect
outcomes in older adults with cancer. This systematic review
and meta-analysis evaluates the association of PP and PIM
with outcomes in older adults with cancer.
MATERIALS AND METHODS
Search Strategy
We followed the PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) guidelines [16]. We
searched for articles from the following databases between
the database inception and September 2018: PubMed, Web
of Science, Embase, and Cochrane Register of Controlled Tri-
als. Standardized terms and keywords were combined in the
search for the following concepts: oncology/cancer, poly-
pharmacy, and inappropriate medications (supplemental
online Appendix 1). Reference lists of relevant articles were
screened to identify other relevant articles (“snowball” sea-
rch). All results were exported to EndNote, and duplicates
were identified and removed.
Selection Criteria
We included studies if they (a) examined any outcomes asso-
ciated with PP and/or PIM; (b) included patients with cancer
(as either the whole sample or a subgroup); (c) included adults
aged ≥65 (a common cutoff to identify older adults in the lit-
erature); (d) were clinical trials, observational cohort studies,
cross-sectional studies, or meta-analyses; and (e) were written
in English. We excluded studies that did not specifically evalu-
ate the associations of PP and/or PIM with outcomes (i.e.,
studies that described the prevalence of PP and/or PIM only)
and those that were published in abstract form only. Two
investigators (M.M. and A.A.) independently reviewed the
titles and abstracts of retrieved articles to select potential arti-
cles. The full texts were further reviewed independently by M.
M. and A.A. for final selection of articles. Disagreements
were resolved by a third investigator (K.P.L.).
Data Extraction and Analysis
A predefined data extraction template was developed and
included name of the first author, year of publication, coun-
try, study design, sample size, age, definition of PP and PIM,
prevalence of PP and PIM, cancer type, treatment planned
or received, outcome variables, and findings on the associa-
tion between PP and PIM and outcome measures. Two inde-
pendent authors (M.M. and A.A., K.P.L., or S.O.) reviewed
full texts of each identified article and extracted the data.
After data extraction, outcomes were categorized into
the following domains: postoperative outcomes, chemother-
apy outcomes, physical function, survival, and miscella-
neous/other outcomes. Odds ratios (OR), p values, and 95%
confidence intervals (CI) were reported for significant results
(defined as p < .05 or 95% CI did not cross 1) if available.
Nonsignificant results are reported as NS, but p values and
OR are not reported as most studies did not report these for
nonsignificant results.
Meta-Analysis
Studies evaluating the association of PP with postoperative
complications used a consistent definition of PP (≥5
medications) and postoperative complications (using the
Clavien-Dindo classification; n = 4 studies) [17]. We per-
formed a random-effects model to combine the OR and 95%
CI in these four studies. Heterogeneity of included studies
was measured using chi-square test and the I2 statistic, with a
significant heterogeneity defined as I2 > 50%. Forest plots
present individual and pooled risk estimates. All statistical
analyses were conducted using Stata 13.0 (Stata Corp, College
Station, TX). Meta-analyses for other outcomes were not
© AlphaMed Press 2019www.TheOncologist.com
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undertaken because of heterogeneity of definitions of PP
and PIM.
Quality Appraisal
Two independent authors (M.M. and A.A., K.P.L., E.R., or S.O.)
assessed the quality of each selected study. We used the
National Institutes of Health (NIH) Quality Assessment Tool for
Observational Cohort and Cross-Sectional Studies [18] as a
guide. We rated the data quality related to PP and PIM and
outcomes as good, fair, or poor. Disagreements among the




The initial search strategy identified 3,459 titles and
abstracts. An additional six articles were identified from the
reference lists of selected articles (Fig. 1). In total, 47 studies
were included (number of patients ranged from 16 to
40,009). These studies were published between 2005 and
2018 from 19 countries. Study designs included retrospective
cohort (23 studies), prospective cohort (14 studies), cross-
sectional (9 studies), and meta-analysis (1 study). Of these
studies, 46.8% (22/47) included patients with only one can-
cer type. Common cancer types were gastrointestinal (GI;
24/47, 51.1%), breast (20/47, 42.5%), and lung (8/47, 17%).
Quality Appraisal
The articles were judged to be good (n = 2, 4.2%), fair (n = 32,
68.1%), or poor quality (n = 13, 27.6%) based on the NIH Qual-
ity Assessment Tool (supplemental online Tables 1 and 2). All
studies clearly stated their research objectives and study pop-
ulation. Sample sizes were clearly stated in all studies; how-
ever, only two studies provided a justification for the sample
size. Only five studies assessed the exposure more than once.
Based on the authors’ judgment, 19 of the 47 articles did not
adequately adjust for potential confounding variables.
Definition and Prevalence of PP and PIM
When defining PP, only 19 studies clearly stated which types
of medications were included in their analyses (i.e., prescrip-
tion, supplemental, and/or over-the-counter medications;
supplemental online Table 1). Overall, the prevalence of PP
ranged from 2.0% to 80.0%. PP was defined as the use of five
or more medications in 57.4% (27/47) of the studies; in these
studies, the prevalence ranged from 14.0% to 80.0%. Other
definitions included (a) 10 or more medications (7/47, with
prevalence ranging from 5.6% to 43.0%), (b) 9 or more medi-
cations (1/47, with no prevalence reported), (c) 6 or more
medications (3/47, 8.0% to 38.0%), (d) 4 or more medications
(4/47, 49.0% to 86.0%), (e) 3 or more medications (2/47,
43.0% to 52.0%), (f) any concomitant (≥1) medications in addi-
tion to cancer treatment (2/47, 2.0%, and 69.0%), and (g)
other definitions (2/47).
Overall, the prevalence of PIM ranged from 19.0% to
52.0% (assessed in 11/47 studies). Ten of 11 studies used the
Figure 1. PRISMA flow diagram. This diagram details our search and study selection process applied during the study according to
PRISMA checklist.
© AlphaMed Press 2019
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Beers criteria to screen for PIM. Several tools were used in
addition to the Beers criteria including Drugs to Avoid in Elderly
(DAE) list (2/47), STOPP criteria (1/47), HEDIS (1/47), National
Board of Health and Welfare Criteria (1/47), and Zhan (1/47).
OUTCOMES
Among all studies, 77.0% (36/47), 6.0% (3/47), and 17.0%
(8/47) investigated outcomes associated with PP, PIM, or
both PP and PIM, respectively. Postoperative outcomes
(e.g., postoperative complications, delirium, extended hospital
stay, and emergency department visit after cancer surgery)
were evaluated in 11/47 studies (23%; Table 1) [19–29]. Che-
motherapy-related outcomes, such as chemotherapy-related
toxicities, chemotherapy completion, hospitalization after che-
motherapy, complete remission (CR), chemotherapy dose
reductions or delay, and blood transfusion, were evaluated
in 12/47 studies (26%; Table 2) [30–41]. Frailty, falls, and
physical and functional outcomes were evaluated in 7/47
studies (15%; Table 3) [42–48]. Survival outcomes were
assessed in 12/47 studies (26%; Table 4) [22, 29, 30, 34, 36,
37, 49–54]. Other outcomes (e.g., medication adherence,
caregiver burden and alternative medications use; supple-
mental online Table 3) [32, 39, 49, 53, 55–63].
Postoperative Outcomes
See Table 1. A meta-analysis of four studies (n = 726 patients
with GI cancers) [19, 21–23] indicated a significant associa-
tion between PP and postoperative complications (overall
OR, 1.9; 95% CI, 1.3–2.8; p = .001; Fig. 2). A study assessing
the relationship between PP and postoperative delirium
found that patients with gynecologic malignancies who
received five or more medications before cancer surgery
were at a higher risk of postoperative delirium (OR, 1.9; 95%
CI, not reported [NR]; p = .008) [24].
Chemotherapy-Related Outcomes
See Table 2. Of the 12 studies that examined the association
between PP and chemotherapy-related outcomes, 9 evaluated
chemotherapy toxicity [31–34, 36, 37, 39–41]. The cancer
types and treatments in these studies were heterogeneous.
Four studies demonstrated that PP was significantly associated
with severe chemotherapy toxicity [33, 36, 37, 39]. In a meta-
analysis of three phase II/III trials by Woopen et al. that
included 1,213 patients with advanced ovarian cancer, PP (≥5
medications) was associated with grade 3–4 hematological
and nonhematological toxicities (OR, 1.1; 95% CI, NR; p < .001)
[37]. In a single-center prospective study of 78 patients with
breast cancer receiving first-line chemotherapy, PP (≥5 medica-
tions) was associated with grade 3–4 toxicities (OR, 6.38; 95%
CI, 2.0–23.5; p = .001) [36]. In a single center retrospective
study of 172 patients with solid tumors receiving irinotecan-
based therapy, the presence of any concomitant drug used to
manage comorbid conditions besides cancer was associated
with grade 4 neutropenia and/or grade 3–4 diarrhea (OR, 4.7;
95% CI, 1.04–21.3; p = .04) [33]. PP (≥6 medications) was also
associated with hospitalization (OR, 2.3; 95% CI, 1.3–3.9;
p = .002) in a single center retrospective study of 318 patients
with solid tumors receiving chemotherapy [40]. Two additional
studies did not demonstrate any association between PP
and hospitalization [30, 31]. PP was not associated with che-
motherapy completion, dose reduction, or delay in four stud-
ies [37, 38, 40, 41].
Frailty, Falls, and Physical and Functional Outcomes
See Table 3. Seven studies examined the association between
PP and frailty, falls, or physical and functional outcomes.
Three studies demonstrated a positive association between
PP and falls [44, 47, 48]. PP was associated with impairment
in either Activity of Daily Living or Instrumental Activity of
Daily Living in three studies [43, 45, 46]. In a single center
cross-sectional study of 385 older patients with various types
of cancers (both solid and hematological), PP (≥5 medica-
tions) was associated with frailty (OR, 4.5; 95% CI, 1.9–10.5;
p = NR) and prefrailty (OR, 2.4; 95% CI, 1.4–3.9; p = NR) [42].
Survival Outcomes
See Table 4. Only two studies demonstrated a positive asso-
ciation between PP and mortality [30, 52]. In a single-center
prospective study of 83 patients with advanced ovarian can-
cer, PP (≥6 medications) was associated with lower overall
survival (OS; OR, NR; 95% CI, NR; p = .04) [52]. In another
single center retrospective study of 150 patients with acute
myeloid leukemia, PP (≥5 medications) was associated with
increased 30-day mortality (OR, 9.98; 955 CI, 1.18–84.13;
p = NR) and overall mortality (hazard ratio [HR], 2.13; 95%
CI, 1.15–3.92; p = NR) [30].
Other Outcomes
See supplemental online Table 3. Of the four studies evaluat-
ing medication adherence, three demonstrated an association
of PP with adherence [39, 55, 57]. In a single center prospec-
tive study of 47 patients with breast cancer, PP (≥4 medica-
tions) was associated with patients receiving nonoperative
radiotherapy despite being a candidate for surgery on univari-
ate analysis (no multivariate analysis was done; OR, NR; 95%
CI, NR; p = .002) [59]. In another multicenter cross-sectional
study, PP was associated with clinical depression (OR, 1.6; 95%
CI, 1.1–2.3; p = .008) [60]. PP was also associated with use of
complementary and alternative medications (OR, NR; 95% CI,
NR; p = .04) and caregiver burden (OR, 2.2; 95% CI, 1.1–4.3;
p = .02) [58, 62]. PP was not associated with impaired geriatric
assessment domains using the Geriatric 8 screening tool, nor
with radiation treatment completion or change in cancer treat-
ment plan [49, 53, 63].
Association of PIM with Outcomes
See Table 5. Among 11 studies [25, 27, 29–32, 45, 54, 58, 64,
65], three demonstrated an association between PIM and clini-
cal outcomes. In a single center retrospective study of 171
patients with aggressive non-Hodgkin lymphoma, PIM use by
Beers criteria was associated with grade ≥ 3 toxicity (HR, 1.02;
95% CI, 1.00–1.04; p = .01), worse progression-free survival
(HR, 2.81; 95% CI, 1.4–5.8; p = .005), and higher mortality (HR,
3.12; 95% CI, 1.5–6.5; p = .003) [64]. In another single center
retrospective study of 475 patients (Beers criteria), PIM was
associated with postoperative delirium (OR, 5.53; 95% CI,
2.02–15.10; p < .001) [27]. A retrospective study that included
7,279 patients with colorectal cancer who underwent cancer
surgery identified an association between PIM (using the
© AlphaMed Press 2019
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National Board of Health and Welfare criteria) [66] and
length of hospital stay (OR, 1.1; 95% CI, 1.0–1.3;
p = .046) and 30-day postoperative mortality (OR, 1.4;
95% CI, 1.1–1.9; p = .006) [29].
DISCUSSION
To the authors’ knowledge, this is the first systematic
review that summarizes the associations of PP/PIM with
outcomes in older adults with cancer. Included studies
were heterogeneous in terms of study design, study popu-
lation, sample size, PP definitions, and outcomes exam-
ined. The wide range of definitions used contributes to the
wide range of PP prevalence reported, from 2% [56] to
80% [45]. PIMs were assessed using the Beers criteria in
the vast majority of the studies, which is the most com-
monly used tool for evaluation of PIMs in both clinical and
research settings; other tools supplemented the use of the
Beers criteria in some studies.
The meta-analysis shows that PP is associated with
postoperative complications using the Clavien-Dindo classi-
fication. In addition, several studies suggest that PP is asso-
ciated with chemotherapy toxicity, frailty, falls, and
medication nonadherence. Most studies did not show
an association between PP and survival, and no studies
showed an association between PP and chemotherapy
completion. PIM is associated with postoperative com-
plications (delirium and readmission), and two studies
indicate that PIM may be associated with higher mortality
and lower progression-free survival [29, 64].
Most studies did not show an association between
PP and survival, and no studies showed an
association between PP and chemotherapy comple-
tion. PIM is associated with postoperative compli-
cations (delirium and readmission), and two studies
indicate that PIM may be associated with higher
mortality and lower progression-free survival.
Other reviews in the general geriatric population have
found a positive association of PP with functional decline
[67, 68]. However, this is the first systematic review to
summarize the association between PP and postoperative
outcomes and chemotherapy toxicity in older adults with
cancer. Because of increased frailty and geriatric syndrome
burden in older adults with cancer, as well as the contribu-
tion of chemotherapy and supportive care regimens to the
overall number of medications, data from general older
adult populations are unlikely to be generalizable.
Four studies assessing the impact of PP on postopera-
tive outcomes used a similar population (patients with gas-
trointestinal cancers), the same definition of PP (≥5
medications), and the same outcome (postoperative com-
plications using the Clavien-Dindo classification). A pooled
analysis of these studies demonstrated that PP was associ-
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of 1.9 (95% CI, 1.3–2.8). This may be due to an increased risk
of adverse drug events and drug-drug interactions in the
presence of anesthetic and other perioperative medications
such as analgesics and antibiotics. In addition, hospitalization
itself is associated with an increased risk of postdischarge
medication-related adverse events [69]. We are unable to
determine which medications or class of medications were
most associated with postoperative complications; medica-
tions assessed as being potentially inappropriate by Beers
criteria or other PIM measures have shown associations with
postoperative length of stay, mortality, and postoperative
delirium across several studies [27, 29], but the effect of PIM
on postoperative complications in older patients with cancer
is unknown.
Similarly, the association between PP and chemotherapy
outcomes remains unclear. Several studies demonstrate that
PP is associated with grade ≥ 3 chemotherapy toxicity, but
other studies failed to show an association with chemotherapy
dose intensity or early discontinuation of therapy. It remains
unclear whether PP affects receipt of chemotherapy and, in
turn, cancer-related survival. This question may be most criti-
cal in older patients being treated with curative intent, for
whom chemotherapy dose delays or reductions may substan-
tially affect survival outcomes. PP increases the risk of clinically
relevant drug-drug interactions which may potentiate chemo-
therapy toxicity and/or adverse drug events [70].
PP was found to be significantly associated with reduced
OS in only 2 out of 11 studies [30, 52]. The lack of associa-
tion in other studies may be due to the advanced stage of
cancer and poor overall prognosis of the included patients.
In very sick patients, PP may be appropriate and may serve
to prolong survival [71]. Competing risk of cancer mortality
is also possible: patients with advanced cancer may die
from their cancer before the adverse effects of PP accrue.
Among the other outcomes evaluated, PP was associated
with improved adherence to adjuvant endocrine therapy [55],
except among patients frequently using opioid-containing anal-
gesics, anxiolytics or antipsychotics, and antidepressants who
had lower adherence to their cancer therapy. This suggests that
certain drug classes may have a disproportionate effect on out-
comes and that a simple count of medications to assess PP




























































































































































































































































































































































































































Figure 2. Meta-analysis. Forest plot for a meta-analysis of stud-
ies evaluated the association of polypharmacy (≥5 medications)
and postoperative complications (using the Clavien-Dindo clas-
sification).
Abbreviation: CI, confidence interval.
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of clinical outcomes [72], and more data are needed to assess
the effects of PP, PIM, and medication burden on adherence,
particularly for the increasing number of oral chemother-
apy agents [73]. It is also possible that medication burden
could impair patients’ ability to adhere to supportive care
regimens, thereby adversely affecting outcomes, but no
data specifically evaluates this hypothesis.
There are limited studies evaluating the association of PIM
with clinical outcomes, and most did not show significant asso-
ciations. Existing criteria and tools to determine PIM are pri-
marily derived from the general geriatric population [74, 75],
and the applicability of these tools in the setting of cancer is
unclear. The time frame for identification of PIM in patients
with cancer may be problematic: many are prescribed support-
ive care medications considered potentially inappropriate in
older adults, although these are usually administered tran-
siently and may be specifically appropriate to treat symptoms
related to cancer or cancer treatment. One study has noted a
transient elevation in PIM prevalence after a lung or colon can-
cer diagnosis, which was mostly due to the use of supportive
care medications [76]. Most current PIM assessment tools con-
sist of explicit criteria which account for little patient context;
assessment of the appropriateness of medications could be
improved with tools using implicit criteria, such as the MAI, but
such tools require time and expertise for application. The MAI
assesses the appropriateness of all medications on a patient’s
list: any medication may be inappropriate within a certain con-
text (such as lack of an ongoing indication for the medication
or lack of time to benefit based on life expectancy).
Two population-based studies were published after our
search and were not included in our systematic review. The
first found an association of PIM (using Beers criteria) with
greater health care utilization and higher health care costs in
a cohort of 17,630 older patients with breast, colorectal, and
prostate cancers [77]. Another study of 3,123 older patients
with breast and colorectal cancers did not find an association
between PIM (using STOPP criteria) and emergency depart-
ment visits, hospitalization, or death [78].
Despite some limited data suggesting that PP/PIM can
affect outcomes in older adults with cancer, it is unknown
whether intervening on PP or PIM can improve outcomes.
There is growing interest in “deprescribing” interventions,
involving planned withdrawal of medications. Deprescribing
has been shown in preliminary studies to reduce the number
of PIMs, falls, and mortality in certain populations. Although
deprescribing has been shown to be feasible in older adults
with cancer, data are lacking about its efficacy [79, 80].
Deprescribing has been shown in preliminary studies
to reduce the number of PIMs, falls, and mortality in
certain populations. Although deprescribing has
been shown to be feasible in older adults with
cancer, data are lacking about its efficacy.
More studies are needed to determine the prospective out-
comes of targeted deprescribing interventions (whether
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determine how these interventions can be implemented for
older adults with cancer, including who should deliver them
(oncologist, pharmacist, or other health care provider).
This review underscores the limited data available to
assess the impact of PP and PIM on outcomes for older
adults with cancer. Prospective data are limited; most studies
are retrospective cohort or cross-sectional studies. Many
studies were not designed with the specific objective to eval-
uate the effects of PP and PIM on outcomes. Many studies
included PP and/or PIM as one of many covariates assessed
(in the setting of geriatric assessment, for example), rather
than as the primary variable of interest; this approach may
be suboptimal for confounding controls and may lead to mis-
interpretation and lack of reproducibility [81]. The studies
are not consistent in their definitions of PP, and most of the
included studies did not specify how they counted the num-
ber of medications. Many medications contributing to the
risk of adverse outcomes are over-the-counter (e.g., diphen-
hydramine) or are typically prescribed on an as needed basis
(e.g., benzodiazepines). Omission of these groups of medica-
tions from the assessment could limit the validity and appli-
cability of the data. In addition, patients who are on more
medications are more likely to have more comorbidities
and/or functional decline, which are important confounders
to consider as they may lead to adverse outcomes; although
some papers adjusted for these factors, it was not always
possible to determine the independent contribution of PP
and PIM. Finally, included studies were not limited to those
enrolling only older adults, most did not assess the potential
for interaction between age and PP and PIM, and studies
included subjects with variable cancer types and other char-
acteristics, which may carry different risks of adverse
outcomes.
Our study has several additional limitations. We did not
include non-English publications, and six studies were not
identified in the initial search, so it is possible that other
studies were missed. Most of the studies were perceived to
have poor to fair quality in relation to the specific objective
of this review. The majority were retrospective or cross-sec-
tional in design, and the causal relationships between PP and
the various outcomes cannot be determined. Most studies
(27/47) evaluated PP in the context of a geriatric assessment
(GA) and included limited information on the medications
(e.g., classes, doses). We were unable to determine if the
results of the GA were available to treating physicians; GA is
known to influence discussion about medications and may
drive medication changes, which in turn may affect out-
comes of interest [82]. Although the majority of the included
studies provided quantitative definition of PP, only about
one-third clearly specified whether prescription, supplemen-
tal, and over-the-counter medications were included.
CONCLUSION
This is the most comprehensive review to date assessing
associations between PP and/or PIM and health outcomes in
older patients with cancer. PP and PIM are prevalent in older
adults with cancer, but definitions are very heterogeneous,
complicating interpretability of associations with outcomes
of interest. PP is associated with postoperative complica-
tions, functional impairment and possibly chemotherapy-
related toxicity, although prospective studies with detailed
medication reviews are needed to further investigate these
associations. Data are very limited for associations with PIM
and outcomes in older patients with cancer, and widely-used
PIM measures may not be as useful in this population. Clear
and validated definitions and instruments are needed to
investigate PP and PIM in older adults with cancer and to
develop interventions, such as deprescribing interventions,
to improve outcomes for these vulnerable patients.
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